Aurangabad, India

Curia – Aurangabad, India

API and intermediate development and manufacturing, with more than 100,000 L of total reactor capacity.

Curia’s Aurangabad facility develops and manufactures active pharmaceutical ingredients and intermediates across a broad range of chemistries. The site pairs specialized capabilities in thiophosgene chemistry and particle size reduction with multi-agency inspection history spanning the FDA, TGA and PMDA.

Facility at a glance

Expertise

190+ experts

An experienced technical and operations team focused on API and intermediate manufacturing.

Total capacity

100,000+ L across units

Unit 2 offers 80,000+ L and Unit 3 offers 20,000+ L of total reactor volume.

Reactor scale

Up to 6,300 L

Individual reactor volumes up to 6,300 L support commercial-scale synthesis.

Batch size

Up to 300 kg

Batch sizes up to 300 kg across a broad range of chemistries.

Compliance

FDA, TGA and PMDA inspected

Inspection history with US, Australian and Japanese regulators supports worldwide supply.

Download

Aurangabad site capabilities overview

What this site does

Safe handling of a demanding reagent

Aurangabad has developed the capability to safely handle thiophosgene, a hazardous chemical used in the manufacture of intermediates and APIs, giving sponsors access to chemistry that many manufacturers avoid.

Micronization below 10 microns

A state-of-the-art micronization facility reduces API particle size with high-volume handling capacity and the ability to achieve particle sizes below 10 microns.

Commercial API and intermediate supply

With more than 100,000 L of combined reactor volume across two units, individual reactors up to 6,300 L and batch sizes up to 300 kg, Aurangabad manufactures APIs and intermediates across a broad range of chemistries.

Inspected by FDA, TGA and PMDA

Multi-agency inspection history supports supply into the US, Australian and Japanese markets, backed by Curia’s worldwide regulatory filing support and DMF/ASMF availability across its generic API network.

Zero liquid discharge

The site treats process wastewater on site under a zero liquid discharge permit, enabling 100% reuse of process wastewater.

Why clients love this site

Chemistry that sets the site apart

Safe thiophosgene handling and sub-10-micron micronization give Aurangabad specialized capabilities within Curia’s API network.

Capacity for commercial supply

More than 100,000 L of combined reactor volume and batch sizes up to 300 kg support dependable commercial manufacture.

Globally inspected quality

FDA, TGA and PMDA inspection history underpins supply into major regulated markets.

Part of a worldwide API network

Aurangabad supplies Curia’s 240+ commercial API portfolio with regulatory filing support worldwide.

How this site fits into Curia’s network

Hyderabad, India – Discovery, development and scale-up

Hyderabad provides discovery chemistry, continuous flow capability and key starting material synthesis for GMP programs, complementing Aurangabad’s manufacturing scale within Curia’s Indian footprint.

Origgio, Italy – European API manufacture

Origgio develops and manufactures APIs and intermediates through chemical synthesis in Europe, with deep hydrogenation and organometallic capability.

Learn More

Valladolid, Spain – Steroids, hormones and sterile APIs

Valladolid contributes specialized steroid and hormone manufacturing, particle size control and aseptic API sterilization to the network’s generic API portfolio.

Learn More